Siobhan provides scientific consultation and execution of cell-based, organism-based, biochemical, phenotypic and stem-cell assays.
Siobhan received her Ph.D. in Chemistry at the University of Iowa and postdoctoral training in molecular pharmacology at UCSD.
View All Publications
Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H₁-antihistamines for insomnia.
Ravula SB, Yu J, Tran JA, Arellano M, Tucci FC, Moree WJ, Li BF, Petroski RE, Wen J, Malany S, Hoare SR, Madan A, Crowe PD, Beaton G
Bioorg Med Chem Lett. 2012 Jan 1;22(1):421-6
Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.
Moree WJ, Li BF, Zamani-Kord S, Yu J, Coon T, Huang C, Marinkovic D, Tucci FC, Malany S, Bradbury MJ, Hernandez LM, Wen J, Wang H, Hoare SR, Petroski RE, Jalali K, Yang C, Sacaan A, Madan A, Crowe PD, Beaton G
Bioorg Med Chem Lett. 2010 Oct 1;20(19):5874-8
Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.
Li BF, Moree WJ, Yu J, Coon T, Zamani-Kord S, Malany S, Jalali K, Wen J, Wang H, Yang C, Hoare SR, Petroski RE, Madan A, Crowe PD, Beaton G
Bioorg Med Chem Lett. 2010 Apr 15;20(8):2629-33
Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors.
Malany S, Hernandez LM, Smith WF, Crowe PD, Hoare SR
J Recept Signal Transduct Res. 2009;29(2):84-93
Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.
Zhang X, Tellew JE, Luo Z, Moorjani M, Lin E, Lanier MC, Chen Y, Williams JP, Saunders J, Lechner SM, Markison S, Joswig T, Petroski R, Piercey J, Kargo W, Malany S, Santos M, Gross RS, Wen J, Jalali K, O'Brien Z, Stotz CE, Crespo MI, Díaz JL, Slee DH
J Med Chem. 2008 Nov 27;51(22):7099-110
Single amino acid residue determinants of non-peptide antagonist binding to the corticotropin-releasing factor1 (CRF1) receptor.
Hoare SR, Brown BT, Santos MA, Malany S, Betz SF, Grigoriadis DE
Biochem Pharmacol. 2006 Jul 14;72(2):244-55
Point mutations identify the glutamate binding pocket of the N-methyl-D-aspartate receptor as major site of conantokin-G inhibition.
Wittekindt B, Malany S, Schemm R, Otvos L, Maccecchini ML, Laube B, Betz H
Neuropharmacology. 2001 Nov;41(6):753-61
Orientation of alpha-neurotoxin at the subunit interfaces of the nicotinic acetylcholine receptor.
Malany S, Osaka H, Sine SM, Taylor P
Biochemistry. 2000 Dec 19;39(50):15388-98
Theoretical and experimental investigations of electrostatic effects on acetylcholinesterase catalysis and inhibition.
Malany S, Baker N, Verweyst M, Medhekar R, Quinn DM, Velan B, Kronman C, Shafferman A
Chem Biol Interact. 1999 May 14;119-120:99-110
Subunit interface selectivity of the alpha-neurotoxins for the nicotinic acetylcholine receptor.
Osaka H, Malany S, Kanter JR, Sine SM, Taylor P
J Biol Chem. 1999 Apr 2;274(14):9581-6
Siobhan Malany's Research Focus
Metabolic Syndrome, Neurodegenerative and Neuromuscular Diseases, Cancer
As Chemical Biology Team Leader in the Conrad Prebys Center for Chemical Genomics at Sanford-Burnham, Florida, Siobhan coordinates the efforts among the HTS, Biology, Chemistry and project management groups at Sanford Burnham and oversees in vitro assay development for uHTS and hit-to-lead development for discovery projects within the NIH Molecular Libraries Probe Center Network portfolio and more recently for R01 collaborative screening grants and the Florida Translational Research Program.
About Siobhan Malany
Dr. Malany has 15 years’ experience in the molecular pharmacology field. Prior to joining Sanford-Burnham, Dr. Malany spent eight years in the biotechnology industry in San Diego, CA driving drug discovery platforms for GPCR, nuclear receptor and kinase enzyme targets in neuroscience, metabolism and inflammation therapeutic areas. Dr. Malany led the high-throughput screening and Biochemistry group at Tanabe Research Laboratories employing my skills in assay development, automation and pharmacological profiling gained from work she conducted at Neurocrine Biosciences to lead pharmacology efforts for several novel drug discovery projects from target validation to lead optimization and IND submissions.
During her graduate and postgraduate studies, Dr. Malany gained extensive training in in vitro molecular pharmacology with a focus on establishing quantitative, mechanistic pharmacological models of protein inhibition. While at the University of Iowa and the University of California, San Diego she developed a model of the transition state for Acetylcholinesterase inhibition and a model of snake toxin binding the nicotinic acetylcholine receptor using thermodynamic mutant cycle analysis. As an Alexander von Humboldt fellow at the Max Planck Institute for Brain Research, she continued her work in receptor pharmacology by elucidating toxin binding of the NMDA receptor.
Honors and Recognition
2012-2013 International Space Station Research Competition Award
2000-2002 Alexander von Humboldt Fellow
1992-1997 Center for Biocatalysis and Bioprocessing Fellow
1997-2000 Tobacco-Related Disease Research Program Fellow